Thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
This article incorporates public domain material from The World Factbook (2025 ed.). CIA. (country: Honk Kong) Hong Kong from BBC News Key Development Forecasts for Hong Kong from International Futures Hong Kong in Transition (1995–2020) Archived 20 March 2025 at the Wayback Machine, an open access photographic archive of recent Hong Kong history Government
The species was first described by English zoologist John Edward Gray in 1842 from a specimen collected at Port Essington in the Northern Territory. Gray saw little distinction from the Egyptian cobra (Naja haje) in his single preserved specimen—excepting the variation in ocular plates—and assigned the name Naja australis. On obtaining a second specimen from the College of Surgeons, Albert Günther of the British Museum recognised an affinity with the Australian species described as Pseudechis porphyriacus, resulting in the current combination as Pseudechis australis in the black snake genus Pseudechis. Scottish-Australian naturalist William Macleay described Pseudechis darwiniensis in 1878, from a more slender specimen that he thought was distinct from P. australis. Belgian-British zoologist George Albert Boulenger described P. cupreus in 1896 from a specimen collected from the Murray River, distinguishing P. darwiniensis from P. australis by the shape of the frontal scale. Austrian zoologist Franz Werner described Pseudechis denisonioides from Eradu, Western Australia in 1909. Australian naturalist Donald Thomson obtained a skull of a large specimen with a wide head collected from East Alligator River in Arnhem Land in 1914, naming it Pseudechis platycephalus in 1933. He distinguished it from P. australis on the basis of it having anteriorly grooved palatine and pterygoid teeth, and having blunt ridges and keels on the dorsal scales. In 1955, Australian herpetologist Roy D. Mackay concluded that several species previously described were synonymous with P.
In addition to Amazon Lockers, Amazon staffed around 30 pickup points in the US and over 800 independent points in India. US locations had large sets of Amazon Lockers and an area for customers to make returns. The India locations were in existing retailers where customers wait for a store employee to retrieve their package. Amazon launched its distribution network in 1997 with fulfillment centers in Seattle and New Castle, Delaware. Amazon has several types of distribution facilities including cross-dock centers, fulfillment centers, sorting centers, delivery stations, Prime now hubs, and Prime air hubs. As of 2018 the US had 75 fulfillment centers and 25 sorting centers with over 125,000 employees. Employees are responsible for:
Sources: en.wikipedia.org
=== Legal status === In April 2025, the European Medicines Agency (EMA) recommended the refusal of a marketing authorization for Winlevi, a medicine intended for treating acne vulgaris. The EMA noted that Winlevi is a new class of medicine that blocks receptors for androgens. However, there is a risk of the medicine suppressing the working of three organs: the hypothalamus and pituitary glands in the brain and adrenal glands. The suppression of these organs could lead to impaired growth and sexual maturation, which is a major concern in adolescents. Although the company presented data to show that the risk was low, the EMA considered that these data, as well as measures the company proposed to minimize the risk, were not sufficient to approve the medicine for people from 12 years of age to less than 18 years of age. In May 2025, Cassiopea requested a re-examination of the EMA's April 2025 opinion. In October 2025, EMA issued marketing authorization for Winlevi.
Prix Galien CEE Pro Bono Humanum Award: In November 2025, Thomsen accepted the Prix Galien CEE Pro Bono Humanum Award on behalf of the Novo Nordisk Foundation, which received the distinction for its contributions to global health initiatives and scientific research. The award was presented at the Central and Eastern Europe edition of the Prix Galien programme in Warsaw, Poland. PwC Business Executive of the Year 2025: In 2025, Thomsen received PwC Denmark's Business Executive of the Year award. The distinction is presented annually to executives in Danish business who have demonstrated notable leadership, strategic influence, and impact on society. PwC's award committee highlighted Thomsen's role in leading the Novo Nordisk Foundation and its expansion of scientific, global health and sustainability initiatives. Golden Plate Award (2024): Golden Plate Award of the American Academy of Achievement, presented by Awards Council member Robert S. Langer. Knight of the Order of the Dannebrog: On December 12, 2022, he was appointed as a Knight of the Order of the Dannebrog by the Danish Royal House
In 2007, Pritzker and his wife donated $5 million to the University of South Dakota to build the Theodore R. and Karen K. Muenster University Center in honor of his wife's parents. In 2011, Milton Academy dedicated the Pritzker Science Center for which Pritzker provided the lead gift. Pritzker is a trustee and serves on the investment committee of Northwestern University. He is a member of the Board of Governors of Northwestern University School of Law. He is a member of the Economic Club of Chicago and the Commercial Club of Chicago. He joined the Duke University Board of Trustees in 2017; his term expires in 2023. On October 22, 2015, Northwestern University School of Law announced that Pritzker and his wife, M. K. Pritzker, had made a $100-million gift to the school in honor of Pritzker's great-grandfather, Nicholas J. Pritzker. The 156-year-old school was renamed the Northwestern Pritzker School of Law. Pritzker received the Spirit of Erikson Institute Award for his creation of the Children's Initiative. Pritzker organized the White House Summit on Early Childhood Education for President Barack Obama in 2014 and helped expand school breakfast programs in Illinois to over 230,000 kids in low income school districts. The Better Government Association, an Illinois watchdog, has criticized Pritzker's charitable giving practices, saying he funneled the funds he gave to charity from offshore tax havens. "The result is that Pritzker's philanthropy, and any accolades that go with it, have been bankrolled with what is essentially found money.
Sources: en.wikipedia.org
==== Ukraine ==== During the Biden administration and the start of the Russian invasion of Ukraine, there were initially significant tensions regarding India's ties with Russia. However, the second Trump administration is anticipated to seek a quick end to the conflict, likely reducing India's distance from the United States on European security issues.
=== European paganism === Among the Germanic tribes, blood was used during their sacrifices; the Blóts. The blood was considered to have the power of its originator, and, after the butchering, the blood was sprinkled on the walls, on the statues of the gods, and on the participants themselves. This act of sprinkling blood was called blóedsian in Old English, and the terminology was borrowed by the Roman Catholic Church becoming to bless and blessing. The Hittite word for blood, ishar was a cognate to words for "oath" and "bond", see Ishara. The Ancient Greeks believed that the blood of the gods, ichor, was a substance that was poisonous to mortals. As a relic of Germanic Law, the cruentation, an ordeal where the corpse of the victim was supposed to start bleeding in the presence of the murderer, was used until the early 17th century.
This revealed the new King Crimson sound, which featured the interlocking guitars of the 1980s mixed with the layered, heavier feel of the 1973–74 line-up. There was also a vague influence from the industrial music of that time. Many of the songs were written or finalised by Belew, and displayed stronger elements of 1960s pop than before; in particular, a Beatles influence. Bruford would refer to this line-up as sounding like "a dissonant Shadows on steroids". As with previous line-ups, new technology was utilised, including MIDI (which Belew and Gunn used to control guitar synthesisers and Fripp used to replace Frippertronics with "Soundscapes") and the Warr Guitar with which Gunn replaced his Chapman Stick in 1995. The double trio began touring on 28 September 1994 in Buenos Aires, Argentina; portions of these concerts were released on the double live CD set B'Boom: Live in Argentina in 1995.
==== Lower side effects ==== Both photosensitizers and photothermal agents have some degree of selectivity for target cells over healthy human cells, but in utilizing both of these mechanisms this selectivity is bolstered. Increased antibiotic efficacy indicates a lower likelihood of requiring follow-up treatments, so the damage is minimal. In addition, some of these combination phototherapeutic agents have antioxidant/reactive oxygen scavenging properties, reducing the amount of collateral damage sustained by the surrounding human cells.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.